Neogenomics (NEO) Long-Term Investments (2020 - 2021)

Neogenomics (NEO) reported Long-Term Investments of $29.6 million for Q1 2021, little changed quarter-over-quarter from $29.6 million in Q4 2020.

Neogenomics (NEO) Long-Term Investments (2020 - 2021) Analysis & Trends

Neogenomics has reported Long-Term Investments for 2 years, with the latest figure at $29.6 million in Q1 2021.

For the quarter ending Q1 2021, Long-Term Investments changed N/A year-over-year to $29.6 million; the trailing twelve-month figure through Mar 2021 stood at $29.6 million (changed N/A YoY), and the FY2020 full-year result was $29.6 million, changed N/A from the prior year.
Long-Term Investments for Q1 2021 stood at $29.6 million, roughly flat from $29.6 million in the prior quarter.
The five-year high for Long-Term Investments was $29.6 million in Q4 2020, with the low at $13.1 million in Q2 2020.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Long-Term Investments (Qtr)
1	Waters	30,529.42 Bn	30,528.96 Bn	1.11 Bn	-
2	Thermo Fisher Scientific	183.75 Bn	180.50 Bn	7.74 Bn	-
3	Danaher	133.13 Bn	127.43 Bn	3.59 Bn	-
4	Idexx Laboratories	46.14 Bn	45.94 Bn	722.74 Mn	-
5	Agilent Technologies	38.20 Bn	36.39 Bn	990.00 Mn	136.00 Mn
6	Natera	31.50 Bn	30.40 Bn	696.04 Mn	-
7	Iqvia Holdings	31.34 Bn	29.36 Bn	1.36 Bn	357.00 Mn
8	Illumina	24.51 Bn	23.36 Bn	721.00 Mn	-
9	Mettler Toledo International	23.53 Bn	23.47 Bn	555.82 Mn	-
10	Neogenomics	1.48 Bn	1.33 Bn	80.86 Mn	-

Download Data